Skip to main content

Published locations for SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’

User login

  • Reset your password
  • /content/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and-nephrologists
  • /emed-journal/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and
  • /familypracticenews/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists
  • /internalmedicinenews/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists
  • /clinicalendocrinologynews/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong
  • /ecardiologynews/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and
  • /cardiology/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and
  • /endocrinology/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and
  • /internalmedicine/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and
  • /familymedicine/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists-and
  • /emergencymedicine/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong-cardiologists
  • /type-2-diabetes-icymi/article/225536/diabetes/sglt2-inhibitors-developed-t2d-now-belong